Medicare Weight-Loss Drug Discount Excludes Sickest Patients
#Medicare #GLP1Medicare's $50 GLP-1 pilot excludes patients with conditions like sleep apnea, routing them to costly Part D plans. Jeff La Marca, morbidly obese and prediabetic, was denied despite high medical need, highlighting affordability gaps in the program's design. read more
Insurance Denies Weight Loss Drugs? Here’s How to Fight Back
#GLP1 #InsuranceCoverageIf your insurance denies GLP-1 weight loss drugs, check fine print for qualifying conditions like sleep apnea. File appeals with doctor support, document care meticulously, seek discounts, and consider compounded options cautiously. Persistence is key. read more
GLP-1 Drugs May Slow Obesity-Related Cancer Spread
#GLP1 #CancerResearchGLP-1 drugs like Ozempic and Wegovy may slow obesity-related cancer spread, a study finds. Researchers observed reduced progression in lung, breast, colorectal, and liver cancers among patients. Further studies are needed to confirm these observational results. read more